Commentary|Videos|March 8, 2024

Yunu Co-Founders Talk Adapting to the Specific Needs of a Clinical Trial and Facilitating Reliable Imaging

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, discuss adapting to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties.

ACT: How does your platform adapt to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties compared to oncology trials?

Sorenson: The unit platform supports all formats of imaging data. The workflows are really the same, whether it's an oncology trial or a trial in another specialty area. So, we're not just specific to oncology. A cardiac trial, for example, can be set up that runs across any of the chosen sites that are already set up on the platform. For example, you can set up additional cardiac specific sites in cardiology practices. Each trial is configured on our platform independently. So, it doesn't matter that those sites are using our platform for oncology clinical trials, you can separately and independently use our platform simultaneously for cardiology, or pulmonology, or gastroenterology trials. When you look at the requirements for that, the things that they need to do is collect data, QC the data, take the measurements, have a physician sign off, and send the data to the study staff and to downstream systems, all of which are supported in our platform today. We're always adding new capabilities to support new modalities, different volumetric use cases, and allow sponsors more control and more visibility over their imaging trials across the entire range of work that they perform in their clinical trials operations.

ACT: Decentralized clinical trials are increasingly important, but imaging can be a major hurdle. How does Yunu facilitate efficient and reliable imaging within a decentralized trial setting?

Kuhn: Yunu is a collaborative ecosystem where the patient scan can be captured in any location. The treating physician being in one place, the treating oncologist in another, and the reading radiologist in yet another with everything synchronized in a single workflow. Also, communication is especially important within decentralized workflow. Yunu provides closed loop workflow with communication that will occur within the platform so everything runs faster.


Related to this article

What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption—and why RBQM only delivers full value when it replaces, not supplements, traditional monitoring.